Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies.

Murray, S., Briasoulis, E., Linardou, H., Bafaloukos, D., Papadimitriou, C.·2012·Cancer Treatment Reviews
DOI 10.1016/j.ctrv.2012.02.011

Cited by (261)

Items 201–261 of 261

  1. DCTPP1 Expression as a Predictor of Chemotherapy Response in Luminal A Breast Cancer Patients
    Juan Pablo Muñoz, Diego Soto-Jiménez, Gloria M. Calaf · 2024 · Biomedicines
  2. Taxanes in combination with biologic agents for ovarian and breast cancers
    Roshan Karki, Brandon-Luke L. Seagle, Wilberto Nieves‐Neira, Shohreh Shahabi · 2013 · Anti-Cancer Drugs
  3. 11a-N-Tosyl-5-deoxi-pterocarpan, LQB-223, a novel compound with potent antineoplastic activity toward breast cancer cells with different phenotypes
    Lauana Greicy Tonon Lemos, Gabriela Nestal de Moraes, Deborah Delbue, Flavia da Cunha Vasconcelos, Paula Sabbo Bernardo, Eric W.‐F. Lam, Camilla Djenne Buarque, Paulo R. R. Costa, Raquel Ciuvalschi Maia · 2016 · Journal of Cancer Research and Clinical Oncology
  4. Reduction of breast tumor drug resistance by 2,3,5,4’-tetrahydroxystilbene for exhibition synergic chemotherapeutic effect
    Yao-Yuan Chang, Hung-Jun Lin, Ling-Chi Hsiao, Yu‐Feng Lin, Chih-Sheng Chang, Der-Zen Liu · 2021 · PLoS ONE
  5. Mechanisms of Drug Resistance and Use of Nanoparticle Delivery to Overcome Resistance in Breast Cancers
    Huseyin Beyaz, Hasan Uludağ, Doğa Kavaz, Nahit Rizaner · 2021 · Advances in experimental medicine and biology
  6. A 20-gene signature in predicting the chemoresistance of breast cancer to taxane-based chemotherapy
    Dongxu He, Yudong Xia, Xiaoting Gu, Jian Jin, Xin Ma · 2014 · Molecular BioSystems
  7. Molecular effects of paclitaxel-elacridar nanoemulsions in breast cancer cells: impact on uptake, cell cycle and signaling pathways
    Giovanna Cassone Salata, Isabella D. Malagó, Giovanna Barros de Melo, João Agostinho Machado‐Neto, Luciana B. Lopes · 2025 · European Journal of Pharmaceutics and Biopharmaceutics
  8. Androgen receptor expression and its prognostic value in T1N0 luminal/HER2- breast cancer
    Wenjing Zhong, Jiarong Yi, Haoming Wu, Xuxiazi Zou, Jikun Feng, Xinjian Huang, Siqi Li, Xi Wang · 2022 · Future Oncology
  9. Transducin-Like Enhancer of Split 3 (TLE3) Expression Is Associated with Taxane Sensitivity in Nonserous Ovarian Carcinoma in a Three-Cohort Study
    Brian Z. Ring, Rajmohan Murali, Robert A. Soslow, David D.L. Bowtell, Sián Fereday, Anna DeFazio, Nadia Traficante, Catherine J. Kennedy, Alison H. Brand, Raghwa N. Sharma et al. · 2018 · Cancer Epidemiology Biomarkers & Prevention
  10. Evidence for P-Glycoprotein Involvement in Cell Volume Regulation Using Coulter Sizing in Flow Cytometry
    Jennifer Pasquier, Damien Rioult, Nadine Abu-Kaoud, Jessica Hoarau-Véchot, Matthieu Marin, Frank Le Foll · 2015 · International Journal of Molecular Sciences
  11. Regulation of DNA Repair Process by the Pro-Inflammatory NF-κB Pathway
    Simarna Kaur, Thierry Oddos, Samantha Tucker‐Samaras, Michael D. · 2013 · InTech eBooks
  12. Effect of substituents at the C3´, C3´N, C10 and C2-meta-benzoate positions of taxane derivatives on their activity against resistant cancer cells
    Petr Daniel, Kamila Balušíková, Jaroslav Truksa, Jiří Černý, Martin Jaček, Michael Jelínek, Mutale Jane Vobruba Mulenga, Kateřina Voráčová, Lei Chen, Longfei Wei et al. · 2024 · Toxicology and Applied Pharmacology
  13. Classical Taxane versus the New Generation, Nab-Paclitaxel Chemotherapy in the Treatment of Breast Cancer
    Ghada Ajabnoor · 2017 · MOJ Cell Science & Report
  14. Paclitaxel in breast cancer – drug resistance and strategies to counteract it
    Alicja Zajdel, Daniel Wolny, Magdalena Kałucka-Janik, Adam Wilczok · 2019 · Postępy Higieny i Medycyny Doświadczalnej
  15. Recent Advances on Nanotechnology Applications to Cancer Drug Therapy
    Carolina L. Bellera, Melisa E. Gantner, María Esperanza Ruiz, Alan Talevi · 2013 · Journal of cancer research updates
  16. Selective Delivery of Clinically Approved Tubulin Binding Agents through Covalent Conjugation to an Active Targeting Moiety
    Samuel E. Collyer, Gary D. Stack, John Jarlath Walsh · 2022 · Current Medicinal Chemistry
  17. Estimation of cancer cell migration in biomimetic random/oriented collagen fiber microenvironments
    Jingru Yao, Guoqiang 国强 Li 李, Xiyao Yao, Lianjie Zhou, Zhikai Ye, Yanping Liu, Dongtian Zheng, Ting 婷 Tang 唐, Kena Song, Guo Chen et al. · 2024 · Chinese Physics B
  18. New uracil analog as inhibitor/modulator of ABC transporters or/and NF-κB in taxol-resistant MCF-7/Tx cell line
    Angelika Długosz-Pokorska, Tomasz Janecki, Anna Ewa Janecka, Katarzyna Gach · 2024 · Journal of Cancer Research and Clinical Oncology
  19. Serum Amyloid A1 Mediates Paclitaxel Resistance via MD2‐Dependent Pathways in Triple‐Negative Breast Cancer
    Kangmin Chen, Yanni Zhao, Tianyang Jin, Tingxin Xu, Conglun Zhu, Hui Shen, Xiaohong Xu, Yongsheng Jiang, Junqing Wang, Shihang Xue · 2025 · Drug Development Research
  20. EM-E-11-4 increases paclitaxel uptake by inhibiting P-glycoprotein-mediated transport in Caco-2 cells
    Qian Liu, Hua Sun, Xiaoguang Chen, Yan Li, Hui Chen, Feng You, Xiu-Qi Bao, Dan Zhang, Jian‐Gong Shi · 2015 · Journal of Asian Natural Products Research
  21. Efficacité, tolérance et coût de l’éribuline chez des patientes présentant un cancer du sein métastatique
    Marie‐Justine Paillard, Elsa Curtit, Erion Dobi, Laura Mansi, Fernando Bazán, Cristian Villanueva, L. Chaigneau, Philippe Montcuquet, Nathalie Méneveau, Antoine Thiery-Vuillemin et al. · 2015 · Bulletin du Cancer
  22. Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
    Richard Wang, Harris H. Wang, Zhixiang Wang · 2017 · Journal of Visualized Experiments
  23. Drug Resistance in Breast Cancer: Characterization of Rationally Designed Paclitaxel Analogs in Model Systems
    Marc C St.George · 2013 · ERA: Education and Research Archive (University of Alberta)
  24. Comparison of the second-line treatment efficacy in advanced gastric cancer patients previously treated with taxane-based triplet chemotherapy: a Turkish Oncology Group Study
    Kadriye Bır Yucel, Muzaffer Uğraklı, Serhat Sekmek, Nilgün Yıldırım, Fatih Gürler, Ozan Yazıcı, Ahmet Özet, Öznur Bal, Murat Araz, Mehmet Artaç et al. · 2024 · Current Medical Research and Opinion
  25. Agar Composition Modulates Production of Trichoderma Peptaibols, Affecting Antibacterial and Antiproliferative Activity
    Patrik Macášek, Adriana Kapustová, Jitka Viktorová, Ján Víglaš, Petra Olejníková, Lukas Grey, Lucia Laubertová, Helena Gbelcová · 2025 · Current Microbiology
  26. Checkpoint Genes in Check: Impact of BUB1, BUB1B, and MAD2 Alterations on the Treatment Outcomes of Advanced Ovarian Cancer
    Sinjini Sarkar, Ranita Pal, Trisha Choudhury, Manisha Vernekar, Puja Chatterjee, Kalyan Kusum Mukherjee, Partha Nath, Santosh Kumar Behera, Sunil Kumar, Vilas D. Nasare · 2025 · Journal of Current Oncological Trends
  27. Vinpocetine Overcomes Paclitaxel Resistance in a Triple‐Negative Breast Cancer Cell Line
    Hsiao‐Hui Kuo, Chien‐Wei Huang, Wei‐Rou Chiang, Ling‐Huei Yih · 2025 · Cell Biology International
  28. Roles of base and nucleotide excision repair activities in cancer treatment: implications for prognosis and resistance to therapy in breast and colorectal cancers
    Ana Rita Guedes, Carlos Martins‐Gomes, Renato Cunha, Amélia Maria Silva, Isabel Gaivão · 2026 · Mutation Research/Genetic Toxicology and Environmental Mutagenesis
  29. Transcript expression and genetic variability analysis of caspases in breast carcinomas suggests CASP9 as the most interesting target
    Veronika Brynychová, Viktor Hlaváč, Marie Ehrlichová, Radka Václavíková, Vlasta Němcová‐Fürstová, Václav Pecha, Markéta Trnková, Marcela Mrhalová, Roman Kodet, David Vrána et al. · 2016 · Clinical Chemistry and Laboratory Medicine (CCLM)
  30. Association between Paclitaxel Clearance and Tumor Response in Patients with Esophageal Cancer
    Eelke L.A. Toxopeus, Femke M. de Man, Nanda C. Krak, Katharina Biermann, Annemieke J.M. Nieuweboer, Lena E. Friberg, Esther Oomen‐de Hoop, J. Jan B. van Lanschot, Joël Shapiro, Bas P. L. Wijnhoven et al. · 2019 · Cancers
  31. 'I get by with a little help from my friends': The role of stromal cells in the breast cancer chemoresistance mechanism
    Helena Abolins-Thompson · 2022
  32. Simultaneous delivery of docetaxel and tariquidar to chemoresistance cancer cells using functionalized lipid nanocarriers
    Chang Hyun Kim, Sang Kil Lee, Ji Yeh Choi, Min Jeong Lyu, Hyun Min Jung, Yoon Tae Goo, Myung Joo Kang, Young Wook Choi · 2022 · Research Square
  33. Metadherin inhibits triple-negative breast cancer chemosensitivity to paclitaxel via activation of the AKT/GSK-3β signaling pathway
    Zhenchuan Song, Yan Chang, Huiqin Jia, Bin Xu, Yang Liu, Yetong Xu, Jingyu Zhang, Meiqi Wang, Lixian Yang · 2022 · Research Square
  34. Biomarkers of Therapeutic Resistance in Breast Cancer
    Sudeep Gupta, Ashish Singh, Bharat Bhosale, Bhawna Sirohi · 2013 · Current Breast Cancer Reports
  35. β-Tubulin is a Predictive Marker of Docetaxel Combined with S-1 in Recurrent or Metastatic Gastric Cancer
    Yuehong Cui · 2014 · Chemotherapy Open access
  36. A Targetable GATA2-IGF2 Axis Confers Aggressiveness in Chemotherapy Resistant Prostate Cancer
    Samuel J. Vidal · 2015
  37. The Involvement of Heat Shock Proteins and Related Molecules in the Resistance to Therapies in Breast and Gynecologic Cancer
    Fernando Darío Cuello-Carrión, Mariel A. Fanelli, Gisela N. Castro, Niubys Cayado-Gutiérrez, Daniel Ramón Ciocca · 2015 · Current Cancer Therapy Reviews
  38. Residual breast cancer metabolic phenotype after docetaxel treatment
    Tatiana Volpari · 2016 · University of Birmingham Institutional Research Archive (University of Birmingham)
  39. Translation to the Clinic: Preclinical and Clinical Pharmacology Studies of Nanoparticles – The Translational Challenge
    Rachel Tyson, Leah Osae, Andrew J. Madden, Andrew T. Lucas, William C. Zamboni · 2016 · Wiley eBooks
  40. Kinome-wide CRISPR-Cas9 screen to identify kinases involved in Taxol resistance in breast cancer
    Tess Montminy · 2016 · QSpace (Queen's University Library)
  41. STUDIES ON THE ANTI-CANCER PROPERTIES OF ARTESUNATE: ANTI-PROLIFERATIVE AND CYTOTOXIC EFFECTS ON BREAST AND OVARIAN CANCER CELLS
    Anna L. Greenshields · 2017 · DalSpace (Dalhousie University)
  42. [Nephrotoxicidad for imatinib].
    C. Díaz Rodríguez, Beatriz Vasco · 2003 · PubMed
  43. Avaliação in vitro das propriedades biológicas do extrato de sementes de Eschweilera ovata (Cambess.) Miers
    Nathália Araújo Rocha · 2021
  44. A critique. B. F. Skinner's behaviorism.
    Richard Dunning · 1972 · PubMed
  45. 3D collagen microchamber arrays for combined chemotherapy effect evaluation on cancer cell numbers and migration
    Jingru Yao, Guoqiang Li, Lianjie Zhou, Shuyan Xu, Kena Song, Hongfei Zhang, Xianquan Zhang, Jianwei Shuai, Fangfu Ye, Ming Li et al. · 2023 · Biomicrofluidics
  46. Fundamentos de farmacología oncológica
    Universidad del Azuay, Edwin Cevallos Barrera, Galo Duque, Universidad del Azuay · 2020
  47. Overcoming Breast Cancer Resistance to Targeted, Chemo-, and Immuno Therapy: Mechanisms and Strategies to Overcome Resistance and Facilitate Drug Development
    Adam Hermawan, Sisca Ucche, Wilfan Ibadurrahman, Kristoforus Patrana Ardi, Chris Djerico · 2024 · Interdisciplinary cancer research
  48. Gene Expression and Pathway Activation Biomarkers of Breast Cancer Sensitivity to Taxanes
    Daniil V. Luppov, Maxim Sorokin, Marianna Zolotovskaya, Marina I Sekacheva, Maria Suntsova, Г. С. Захарова, Anton A. Buzdin · 2024 · Biochemistry (Moscow)
  49. STAMBP as a potential contributor of docetaxel resistance and prognostic biomarker in breast cancer
    Pei‐Yi Chu, Hung-Yu Lin · 2025 · 童綜合醫學雜誌
  50. Additional file 1 of Synergistic co-administration of docetaxel and curcumin to chemoresistant cancer cells using PEGylated and RIPL peptide-conjugated nanostructured lipid carriers
    Chang Hyun Kim, Byoung Deok Kim, Lee, Tae Hwa, Hyeon Kyun Kim, Min Jeong Lyu, Yoon, Young In, Goo, Yoon Tae, Kang, Myung Joo, Sangkil Lee, Choi, Young Wook · 2022 · Figshare
  51. Additional file 2 of Kinase shRNA screening reveals that TAOK3 enhances microtubule-targeted drug resistance of breast cancer cells via the NF-κB signaling pathway
    Lai, Tsung-Ching, Fang, Chih-Yeu, Jan, Yi-Hua, Hsieh, Hsiao-Ling, Yang, Yi-Fang, Liu, Chun-Yu, Chang, Peter Mu-Hsin, Hsiao, Michael · 2020 · Figshare
  52. Association of low HER2 expression with specific mortality risk in early-stage breast cancer: A competing risk analysis of 2645 patients
    Joseph Lin, Hsin-Ya Huang, Yu-Fen Wang, S. T. Chen, Yu‐Jun Chang, Han‐Tsang Wu, Wei-Chung Shia, Hsin-Shun Tseng, Dar-Ren Chen · 2026 · Asian Journal of Surgery
  53. Immunohistochemical biomarkers to predict adjuvant chemotherapy response in patients with early breast cancer in the MATADOR trial (BOOG 2005-02)
    Mark Opdam, N. Ultee, Jill J.J. Geenen, Annelot G.J. van Rossum, Ingrid A.M. Mandjes, Sara Balduzzi, Ingrid Hofland, Jelle Wesseling, Renee Xavier de Menezes, Hendrika M. Oosterkamp et al. · 2026 · The Breast
  54. MACBETH : MACrophages BoostEd THerapy : Stratégie de réactivation des macrophages au sein de la tumeur via l’inhibition de proproteines convertases et la stimulation de TLRs
    Mélanie Rose · 2020
  55. Beyond Breast Cancer : The Interplay of Immunity, Comedications, and Comorbidities in Treatment Response and Outcomes
    Beatriz Grandal · 2023 · theses.fr (ABES)
  56. Targeting the cell cycle : A novel therapeutic strategy against ATIP3- deficient breast cancer
    Maria M. Haykal · 2023 · theses.fr (ABES)
  57. Artificial intelligence and machine learning approaches in rational drug design to overcome cancer chemoresistance
    Sanjana Mishra, Prekshi Garg, Anshul Tiwari, Prachi Srivastava · 2026 · Elsevier eBooks
  58. Integrating multi-omics and clinical management in breast cancer: a comprehensive review
    Xiangxiang Cao, Y F Yang, Pengbo Wang, J L Wang, Yike Zhao, Zichun Zhang, Jiaqi Jiang, Hanwen Zhang, Xinyao Kang, Huigen Feng et al. · 2026 · Discover Oncology
  59. The functional dichotomy of exosomal microRNAs in TNBC: implications for chemoresistance and integrated theranostics
    Afreen Aftab, Sumathy Arockiasamy, K Satish Srinivas, Sundersingh Shirley, V. Pavithra, Ravichandran Ambalathandi · 2026 · Molecular Biology Reports
  60. BindingDB Entry 50006505: An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer.
    BindingDB · 2020 · UC San Diego
  61. BindingDB Entry 50022096: Selective Aurora A-TPX2 Interaction Inhibitors Have In Vivo Efficacy as Targeted Antimitotic Agents.
    BindingDB · 2025 · UC San Diego